Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

Bryan A Faller, Barbara BurtnessDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAAbstract: Pancreatic adenocarcinoma is a common malignancy that remains refractory to available therapies. Gemcitabine has long been the standard, first-line agent in advanced disease. The e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bryan A Faller, Barbara Burtness
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/90b8799b8dd04c1cb305dd9a708ac4e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:90b8799b8dd04c1cb305dd9a708ac4e9
record_format	dspace
spelling	oai:doaj.org-article:90b8799b8dd04c1cb305dd9a708ac4e92021-12-02T05:07:43ZTreatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy1177-54751177-5491https://doaj.org/article/90b8799b8dd04c1cb305dd9a708ac4e92009-09-01T00:00:00Zhttp://www.dovepress.com/treatment-of-pancreatic-cancer-with-epidermal-growth-factor-receptor-t-a3546https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Bryan A Faller, Barbara BurtnessDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAAbstract: Pancreatic adenocarcinoma is a common malignancy that remains refractory to available therapies. Gemcitabine has long been the standard, first-line agent in advanced disease. The epidermal growth factor receptor (EGFR) is a commonly expressed target in pancreatic cancer that is involved in tumor proliferation, metastasis, and induction of angiogenesis. The addition of the EGFR inhibitor erlotinib to gemcitabine has recently been demonstrated to provide a small, yet statistically significant, survival benefit in advanced disease. This has prompted further research into the applications of EGFR-targeted therapy in pancreatic cancer, albeit with disappointing results. Resistance to these therapies seems highly prevalent and has been implicated in their limited efficacy. The development of rash is associated with treatment efficacy and suggests that predictive factors may one day be identified to guide appropriate patient selection for these agents. Preclinical research has shown promise that resistance to EGFR-targeted therapies can be overcome through a variety of approaches. Application of this research in clinical trials may ultimately yield an unquestioned role for EGFR-targeted therapy in the management of this disease.Keywords: cetuximab, drug resistance, epidermal growth factor receptor, erlotinib, gemcitabine, pancreatic cancer Bryan A FallerBarbara BurtnessDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 419-428 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Bryan A Faller Barbara Burtness Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
description	Bryan A Faller, Barbara BurtnessDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAAbstract: Pancreatic adenocarcinoma is a common malignancy that remains refractory to available therapies. Gemcitabine has long been the standard, first-line agent in advanced disease. The epidermal growth factor receptor (EGFR) is a commonly expressed target in pancreatic cancer that is involved in tumor proliferation, metastasis, and induction of angiogenesis. The addition of the EGFR inhibitor erlotinib to gemcitabine has recently been demonstrated to provide a small, yet statistically significant, survival benefit in advanced disease. This has prompted further research into the applications of EGFR-targeted therapy in pancreatic cancer, albeit with disappointing results. Resistance to these therapies seems highly prevalent and has been implicated in their limited efficacy. The development of rash is associated with treatment efficacy and suggests that predictive factors may one day be identified to guide appropriate patient selection for these agents. Preclinical research has shown promise that resistance to EGFR-targeted therapies can be overcome through a variety of approaches. Application of this research in clinical trials may ultimately yield an unquestioned role for EGFR-targeted therapy in the management of this disease.Keywords: cetuximab, drug resistance, epidermal growth factor receptor, erlotinib, gemcitabine, pancreatic cancer
format	article
author	Bryan A Faller Barbara Burtness
author_facet	Bryan A Faller Barbara Burtness
author_sort	Bryan A Faller
title	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
title_short	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
title_full	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
title_fullStr	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
title_full_unstemmed	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
title_sort	treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/90b8799b8dd04c1cb305dd9a708ac4e9
work_keys_str_mv	AT bryanafaller treatmentofpancreaticcancerwithepidermalgrowthfactorreceptortargetedtherapy AT barbaraburtness treatmentofpancreaticcancerwithepidermalgrowthfactorreceptortargetedtherapy
_version_	1718400605221814272

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

Ejemplares similares